Table 2.
Reported Median Overall Survival and Median Progression Free Survival in HCC Immunotherapy Real-World Studies
| Reference | Arm-1 | Median OS/ Median PFS (Months) | Arm-2 | Median OS/ Median PFS (Months) | Comments |
|---|---|---|---|---|---|
| DeCastro et al 202263 | IMBrave-in | 15/ 8.7 | IMBrave-out | 6/ 3.7 | IMBrave-out group showed increased risk for ascites and hepatic encephalopathy |
| Rimini et al, 202364 | IMBrave-in | 16.3/ 8.3 | IMBrave-out | 14.3/ 6 | No statistically significant difference in safety profile |
| Tanaka et al, 202265 | Atezolizumab + Bevacizumab in CP-A | NR/ 9.5 | Atezolizumab + Bevacizumab in CP-B | 14/ 5.1 | Therapeutic efficacy correlated with worsening liver function (mALBI score grade 2b-3). |
| Kim et al, 202266 | Atezolizumab + Bevacizumab in CP-A | NR/ 6 | Atezolizumab + Bevacizumab in CP-B | 6/ 3 | CP-B showed increase rate of grade 3 adverse effects compared to CP-A |
| D’Alessio et al, 202267 | Atezolizumab + Bevacizumab in CP-A | 16.8/ 7.6 | Atezolizumab + Bevacizumab in CP-B | 6.7/ 3.4 | |
| Cheon et al, 202368 | Atezolizumab + Bevacizumab in CP-A | NR/ 9.6 | Atezolizumab + Bevacizumab in CP-B | 7.7/ 3 | CP-B showed increase rate of grade 3 adverse effects compared to CP-A |
| Rimini et al, 202369 | Atezolizumab + Bevacizumab in CP-B | 8.2/ 6.9 | Lenvatinib in CP-B | 13.8/ 8.2 | No statistically significant difference in PFS |
| Casadei-Gardini et al, 202370 | Atezolizumab + Bevacizumab | 16.4 (OS) | Lenvatinib | 16.1 (OS) | ATE/BEV improved OS in HCC patients with viral etiology. Lenvatinib improved OS in HCC patients with NASH/ NAFLD etiology. |
| Wong et al, 202171 | Single agent Nivolumab/ Pembrolizumab in CP-B | 3.1 (OS) | Single agent Nivolumab/ Pembrolizumab in CP-C | 1.7 (OS) | ORR for CP-B and CP-C was 6.8% and 0% respectively. TTP 2.1 and 1.4 months, respectively. |
| Fessas et al, 202072 | Nivolumab in CP-A | 16.3 (OS) | Nivolumab in CP-B | 7.3 (OS) | |
| Chapin et al, 202373 | Nivolumab in CP-B | 5 (OS) | Sorafenib in CP-B | 4 (OS) | Decreased hazard of death with nivolumab compared to sorafenib HR: 0.69 |
Abbreviations: OS, overall survival; PFS, progression free survival; ORR, objective response rate; TTP, time to progression; HR, hazard ratio; NR, not reached; ATE, atezolizumab; BEV, bevacizumab; CP, Child-Pugh; mALBI, modified albumin-bilirubin score.